An Unexpected Visitor

      For patients with advanced HIV infection, the environment is teeming with potentially dangerous pathogens. A 48-year-old male with AIDS (as indicated by his CD4 count) presented to the hospital with the chief complaint of shortness of breath. His CD4 count was 87 cells/mm3; his viral load was>100,000 HIV RNA copies/mL; he had never been treated with highly active antiretroviral therapy; and he was not compliant with trimethoprim/sulfamethoxazole prophylaxis for opportunistic infections. He also reported a skin lesion on the face that appeared approximately 2 months prior to admission without any history of trauma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Thoracic Society
        Diagnosis and treatment of disease caused by nontuberculous mycobacteria.
        Am J Resp Crit Care Med. 1997; 156: 1-25
        • Marras T.K.
        • Morris A.
        • Gonzalez L.C.
        • Daley C.L.
        Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus.
        Am J Respir Crit Care Med. 2004; 170: 793-798
        • Canueto-Quintero J.
        • Caballero-Granado F.J.
        • Herrero-Romero M.
        • et al.
        Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study.
        Clin Infect Dis. 2003; 37: 584-590
        • Lillo M.
        • Orengo S.
        • Cernoch P.
        • Harris R.L.
        Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience.
        Rev Infect Dis. 1990; 12: 760-767
        • Breathnach A.
        • Levell N.
        • Munro C.
        • et al.
        Cutaneous Mycobacterium kansasii infection: case report and review.
        Clin Infect Dis. 1995; 20: 812-817
        • Smith M.B.
        • Molina C.P.
        • Schnadig V.J.
        • et al.
        Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome.
        Arch Pathol Lab Med. 2003; 127: 554-560
        • Griffith D.E.
        • Brown-Elliott B.A.
        • Wallace Jr, R.J.
        Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.
        Clin Infect Dis. 2003; 37: 1178-1182
        • Wallace Jr, R.J.
        • Dunbar D.
        • Brown B.A.
        • et al.
        Rifampin-resistant Mycobacterium kansasii.
        Clin Infect Dis. 1994; 18: 736-743
        • Guna R.
        • Munoz C.
        • Dominguez V.
        • et al.
        In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
        J Antimicrob Chemother. 2005; 55: 950-953